XM does not provide services to residents of the United States of America.
R
R

Regeneron

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug

China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug Nov 20 (Reuters) - Eli Lilly LLY.N and Hong Kong-listed Laekna 2105.HK will collaborate to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle, the biotech said on Wednesday. WHY IT MATTERS Lilly is aiming to strengthen its position as a leader in the obesity treatment market, which is expected to hit $150 billion in revenue by the next decade.
R

Dupixent SBLA Accepted For FDA Review For Treatment Of Chronic Spontaneous Urticaria

BRIEF-Dupixent SBLA Accepted For FDA Review For Treatment Of Chronic Spontaneous Urticaria Nov 15 (Reuters) - Sanofi SA SASY.PA : PRESS RELEASE: DUPIXENT SBLA ACCEPTED FOR FDA REVIEW FOR THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA FDA DECISION ON DUPIXENT EXPECTED BY APRIL 18, 2025 SAFETY RESULTS IN ALL LIBERTY-CUPID PHASE 3 STUDIES WERE GENERAL
R
S

Regeneron To Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types Of Blood Cancers And Disorders At ASH

BRIEF-Regeneron To Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types Of Blood Cancers And Disorders At ASH Nov 13 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : REGENERON TO HIGHLIGHT PIONEERING PIPELINE PROGRESS ACROSS MULTIPLE MODALITIES SPANNING 10 TYPES OF BLOOD CANCERS AND DISORDERS AT ASH Source text: nGN
R

U.S. Amazon, IQVIA Holdings, Uber

U.S. RESEARCH ROUNDUP-Amazon, IQVIA Holdings, Uber Nov 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amazon, IQVIA Holdings and Uber, on Friday. HIGHLIGHTS * Amazon AMZN.O : JP Morgan raises target price to $250 from $230 * Cheniere Energy Inc LNG.N : Raymond James raises target price to $225 from $210 * IQVIA Holdings Inc IQV.N : TD Cowen cuts target price to $255 from $270 * Regeneron Pharmaceuticals Inc REGN.O
A
A
C
E
I
K
R
A
A
E
G
U
A
A
A
I

U.S. Amazon, IQVIA Holdings, Uber

U.S. RESEARCH ROUNDUP-Amazon, IQVIA Holdings, Uber Nov 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amazon, IQVIA Holdings and Uber, on Friday. HIGHLIGHTS * Amazon AMZN.O : JP Morgan raises target price to $250 from $230 * Cheniere Energy Inc LNG.N : Raymond James raises target price to $225 from $210 * IQVIA Holdings Inc IQV.N : TD Cowen cuts target price to $255 from $270 * Regeneron Pharmaceuticals Inc REGN.O
A
C
E
I
K
R
U
A
A
S
E
G
U
I

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.